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The effects of lysine peptide lengths on DNA and
siRNA packaging and delivery were studied using four
linear oligolysine peptides with 8 (K8), 16 (K16), 24
(K24) and 32 (K32) lysines. Oligolysine peptides with 16
lysines or longer were effective for stable monodis-
perse particle formation and optimal transfection effi-
ciency with plasmid DNA (pDNA), but K8 formulations
were less stable under anionic heparin challenge and
consequently displayed poor transfection efficiency.
However, here we show that the oligolysines were not
able to package siRNA to form stable complexes, and
consequently, siRNA transfection was unsuccessful.
These results indicate that the physical structure and
length of cationic peptides and their charge ratios are
critical parameters for stable particle formation with
pDNA and siRNA and that without packaging, delivery
and transfection cannot be achieved.
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Delivery of nucleic acids to cells is a powerful tool for basic
biological research as well as offering the potential for ther-
apeutic development. siRNA delivery in particular is of
intense, widespread interest because of the high degree of
specificity and potency of these molecules in suppressing
gene expression (1). Cationic polymers and liposomes for
nanoparticle formulation with siRNA have been widely
reported for cell delivery, but improved formulations for
in vivo delivery are required (2). Optimal siRNA formulations
should package siRNA efficiently into stable nanoparticles
that bind and enter cells, escape degradation in the
endosome and release the siRNA into the cytoplasm where
the mRNA and silencing machinery are located (3–5).
Although both are nucleic acids, DNA and siRNA pose
very different challenges in the requirements of a polyca-
tionic packaging agent. The most evident is the much lar-
ger size of pDNA, and the other is the subcellular site
required for activity with plasmids required in the nucleus.
Plasmids may be in the range 4–10 kb of double-stranded
DNA, while siRNAs are typically 21–23 nucleotides of dou-
ble-stranded RNA so even a single plasmid may provide a
focus for aggregation, while many copies of siRNA may be
required for the assembly of stable structures and may not
be able to form self-assembling monodisperse complexes.
A cationic charge and a small size, 50–200 nm, are crucial
for cellular uptake (6–8). Once internalized within the cells,
the nucleic acids need to be released at their appropriate
subcellular compartments, with pDNA localized to the
nucleus for gene expression and siRNA guided to the pro-
cessing body (P-body) in the cytoplasm for gene silencing
(3–5).
Oligolysine peptides have been used widely to form com-
plexes with nucleic acids, especially with pDNA (9–21);
however, studies on using oligolysines for siRNA delivery
are limited (22). Oligolysines are an attractive carrier for
gene delivery due to the ease of producing such peptides
as a monodisperse species in high purity and yield by
solid-phase peptide synthesis, which is very difficult to
achieve for longer polylysine chains. We and others have
therefore developed methods to modify these oligopep-
tides with different binding ligands and lipid components
for an improved functionality such as cell targeting for
gene and drug delivery (23–25). However, at present, the
knowledge regarding which oligolysines would be optimal
for nucleic acid delivery, especially for siRNA, is limited.
Therefore, we are the first to perform a systematic study
on the oligolysines (K8, K16, K24 and K32) to identify the
optimal length for pDNA and siRNA delivery. We hypothe-
size that siRNA has different packaging and delivery
requirements compared to pDNA because of the struc-
tural and chemical differences. Therefore, we used the
chemically well-defined oligolysine peptides as a model
system to systemically dissect the differences between
siRNA and pDNA packaging and delivery. Understanding
the effects of the cationic peptide structure on DNA and
siRNA delivery will provide novel insights into the future
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development and improvement of nucleic acid delivery
systems.
Materials and Methods
Transfection reagents and cells
Plasmid pCEP4-Luc, which was used to generate Neuro-
2A cells stably expressing luciferase, consists of pCEP4
plasmid with the luciferase gene from pGL3 (Invitrogen,
Paisley, UK) (1). The pCI-Luc was created by subcloning
the luciferase gene into the pCI plasmid (Promega,
Southampton, UK). siRNAs targeting firefly luciferase
(siLuc) (GAUAUGGGCUGAAUACAA) (26) and EGFP
(siEGFP) (GACGUAAACGGCCACAAGUUC) (27) were syn-
thesized from Dharmacon, Inc (Epsom, UK). The linear
lysine peptides used included 8 (K8), 16 (K16), 24 (K24)
and 32 (K32) lysines in a row, and they were purchased
from ImunnoKontact (Abingdon, UK). Neuro-2A and
Neuro-2A-luciferase cells were cultured in DMEM supple-
mented with 10% foetal calf serum, 1% non-essential
amino acids and sodium pyruvate at 37 °C in humidified
atmosphere in 5% carbon dioxide.
Gel retardation assay
pDNA or siRNA (0.2 lg) was used to form complexes with
the linear lysine peptides at different N/P ratios. The com-
plexes were mixed with the loading dye (4 lL) following
30 min of complex formation at room temperature. pDNA
complexes were loaded onto a 1% agarose gel, and
siRNA complexes were loaded onto a 4% agarose gel for
electrophoresis.
PicoGreen fluorescence quenching experiments
PicoGreen reagent (1:150 w/v) (Invitrogen) was added to
the pDNA or siRNA (0.2 lg) in TE buffer at room tempera-
ture for 10 min. The pDNA or siRNA was then mixed with
the linear lysine peptides to form complexes in TE buffer
at room temperature for 30 min. A fluorescence plate
reader, Fluostar Optima (BMG Labtech, Aylesbury, UK),
was used to analyse the quenched fluorescence. To per-
form the heparin-mediated complex dissociation assays,
heparin sulphate (Sigma-Aldrich, Gillingham, UK) was
added to the complexes formulated in the PicoGreen fluo-
rescence quenching experiments in a range of concentra-
tions (0.02, 0.04, 0.08, 0.16, 0.32, 0.65 and 1.3 U/mL).
The naked pDNA or siRNA labelled with PicoGreen was
used to normalize the PicoGreen signal detected from the
complexes, and values are expressed as percentage rela-
tive fluorescence units (RFU).
Particle sizing and zeta potential measurement
pDNA or siRNA (10 lg) was added to the lysine peptides
at different N/P ratios at room temperature, and the
complexes were transferred to a low-volume transparent
cuvette. The hydrodynamic size was recorded and anal-
ysed by dynamic light scattering (Malvern Nano ZS, Mal-
vern, UK) using the Mark-Houwink parameters, while the
zeta potential was measured by laser Doppler anemometry
(LDA) using the Smoluchowski model. DTS, version 5.03,
which was provided by the manufacturer, was used for
data processing.
Transmission electron microscopy
For the electron microscopy investigations, the nanocom-
plexes were prepared as described above (at an N/P ratio of
3:1 for pDNA complexes and 4:1 for siRNA complexes) and
were applied onto a glow-discharged 300-mesh copper grid
coated with a Formvar/carbon support film (Agar Scientific,
Stansted, Essex, UK). After a few seconds, the grid was
dried by blotting with filter paper. The sample was then neg-
atively stained with 1% uranyl acetate for a few seconds,
before blotting with filter paper and air-dried. Imaging was
carried out under a Philips CM120 BioTwin Transmission
Electron Microscope (FEI, Eindhoven, Netherlands) and
operated at an accelerating voltage of 120 KV.
pDNA and siRNA transfection
For pDNA transfection, 1 9 104 Neuro-2A cells were
seeded in 96-well plates at each well 24 h prior to trans-
fection. The transfection complexes were formed by mix-
ing the linear lysine peptides with pCI-Luc (0.25 lg/well) at
a range of N/P ratios in OptiMEM (Invitrogen) and incu-
bated for 30 min at room temperature. The transfection
procedure was performed for 4 h at 37 °C, and the trans-
fection complexes were then replaced with the full growth
medium. The cells were cultured for 24 h before the luci-
ferase expression analysis.
For siRNA (luciferase-targeting) transfections, 1 9 104
Neuro-2A-luciferase-expressing cells (Neuro-2A-Luc) were
seeded in 96-well plates at each well 24 h prior to trans-
fection. To form the siRNA complexes, the linear lysine
peptides were added to siLuc or siEGFP (2.4 pmol) at dif-
ferent N/P ratios in OptiMEM and incubated for 30 min.
Following the removal of growth medium on the Neuro-
2A-Luc cells, the complexes were added to the cells and
incubated for 4 h at 37 °C and then the medium was
replaced by the full growth medium and cultured for 24 h.
Lipofectamine 2000 (Invitrogen) was used as a control,
and the transfection procedures were performed in accor-
dance with the manufacturer’s instructions.
Luciferase assay
The transfected cells were harvested for luciferase assays
to determine the transfection efficiency. The luciferase
activity in the cells were measured by a luciferase assay
system (Promega) using a Fluostar Optima luminometer
(BMG Labtech). To normalize the luciferase signal from the
cells, protein content of cell lysates was measured by the
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Bio-Rad protein assay reagent (Bio-Rad, Hemel Hemp-
stead, UK). Luciferase activity was expressed as RLU per
milligram of protein (RLU/mg).
Flow cytometry and confocal microscopy
pCI-Luc was labelled with a Cy5 tag following the manufac-
turer’s instructions (Mirus, Cambridge, UK). The Cy5-labelled
pDNA (1 lg in 500 lL) was used to transfect 2 9 105
Neuro-2A cells in a well of a 12-well plate for 4 h. The cells
were then trypsinized and washed gently with PBS three
times and labelled with propidium iodide (PI) (Invitrogen). The
cells were analysed by the Epics XL flow cytometer (Beck-
man, High Wycombe, UK). For confocal microscopy, the
Neuro-2A cells transfected with Cy5-labelled pDNA com-
plexes were trypsinized and washed gently with PBS three
times. The cells were transferred to a slide coated with poly-
lysine and incubated for 30 min at 37 °C. Following washing
with PBS three times, the cells were fixed with 4% formalde-
hyde for 20 min at room temperature and permeabilized with
0.5% Triton in PBS for 5 min at room temperature. The cells
were then stained with Alexa Fluor 488 phalloidin (Invitrogen)
and DAPI (Vector Labs, Peterborough, UK). The slides were
visualized using a confocal microscope (Leica-Microsys-
tems, Wetzlar, Germany).
Cell proliferation assay
Cell viability was assessed in 96-well plates using the Cell-
Titer 96 Aqueous One Solution Cell Proliferation Assay
(Promega). Neuro-2A cells were seeded and transfected
as above, and then after 24 h, the medium was substi-
tuted for a growth medium containing 20 lL of the CellTi-
ter 96 Aqueous One Solution reagent. Finally, after
incubation for 2 h, the absorbance at 490 nm was mea-
sured on a FLUOstar Optima spectrophotometer (BMG
Labtech). Cell viability for each complex was expressed as
a percentage of the viability of control cells.
Statistical analysis
Data presented in this study were analysed using a two-
tailed, unpaired Student’s t-test where applicable.
Results
Linear lysine peptides packaged pDNA, but not
siRNA
To examine and compare the binding capacity of the
lysine-based peptides with pDNA or siRNA, gel retardation
and PicoGreen fluorescence quenching assays were per-
formed.
Gel retardation assay
pDNA complexes were prepared with the four lysine pep-
tides at a range of N/P charge ratios from 0.15 to 24 and
analysed for changes in the mobility and ethidium bromide
staining intensity of pDNA by agarose gel electrophoresis.
All the linear lysine peptides (K8, K16, K24 and K32)
bound and retarded pDNA with complete retardation in
the well (Figure 1A,B). K8, K16 and K24 completely
retarded the pDNA migration at the same N/P ratio of 3:1,
while K32 achieved the same retardation at an N/P ratio of
1.5:1. A further increase of the N/P ratio for peptide/pDNA
complexes with K16, K24 and K32, but not K8, reduced
the ethidium bromide fluorescence intensity in the well of
the agarose gel, suggesting fluorescence quenching by
further pDNA association. This experiment suggested that
K16 was the minimum oligolysine length for optimal pDNA
packaging.
A more variable effect of oligolysine length and charge
ratio on gel retardation of siRNA was observed (Figure 1C,
D). K8 provided a minimal retardation of siRNA compared
to the siRNA control even at an N/P ratio of 128:1 (Fig-
ure 1C). K16 provided increasing degrees of retardation at
increasing charge ratios as evidenced by a smear of
increasing length, indicating siRNA complexes of higher
molecular weight and/or lower negative charge due to
increased peptide association (Figure 1C). K16 could not
completely retard siRNA migration even up to an N/P ratio
of 128:1, suggesting that siRNA cannot be fully packaged
by these peptides. Retardation of siRNA by K24 and K32
peptides increased up to N/P ratios of 16:1 with more
compact smearing patterns than those observed with
K16, and the complexes were completely retarded in the
wells at 16:1 (Figure 1D). Interestingly, at higher charge
ratios of the K24 and K32 siRNA complexes (N/P ratios of
32, 64 and 128), siRNA migrated towards the cathode
indicating the formation of cationic complexes.
PicoGreen fluorescent quenching assay
The binding of lysine peptides to pDNA or siRNA can be
assessed by the PicoGreen fluorescent quenching assay.
In this assay, pDNA or siRNA were labelled with the Pico-
Green fluorescent dye and then mixed with the lysine pep-
tides. Quenching of the fluorescence indicates packaging
of the nucleic acid. By comparing the remaining fluores-
cence of oligolysine complexes with pDNA or siRNA with
the fluorescence of naked nucleic acid, the percentage of
binding of the pDNA/siRNA by the lysine peptides can be
calculated.
With pDNA, the lysine peptides achieved maximal quench-
ing of the PicoGreen signal at an N/P ratio of 3 (Figure 2A)
with K8, K16, K24 and K32 quenching the fluorescence
down to 26%, 17%, 12% and 10% of naked pDNA,
respectively (see Figure S1A for the quenching signal at
lower N/P ratios). For siRNA, the lysine peptide siRNA
complexes all achieved their maximal quenching of the
PicoGreen fluorescence at the N/P ratio of 3 (Figure 2B).
K8 quenched the PicoGreen signal to 19% of the control,
while K16, K24 and K32 decreased the RFU to 5%, 3%
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and 2% of the naked control, respectively (See Figure S1B
for the quenching signal at lower N/P ratios). There is a
discrepancy between the siRNA packaging data from the
gel retardation assay and the PicoGreen fluorescence
quenching assay. During the gel retardation assay, an
electric field was applied across the siRNA complexes. As
a result, the electrophoretic forces would influence the
migration patterns of the complexes dependent on the
overall charge of the complexes and the binding strength
between cationic peptides and siRNA (i.e. the siRNA
migrated to the anode, while the peptides migrated to the
cathode). The smear patterns in the gel indicated that
either (i) the binding between the peptides and siRNA was
too weak and therefore the components of the complexes
were being pulled apart by the electrophoretic forces or (ii)
the siRNA complexes were heterogeneous in terms of size
and charge. However, such an external ‘pulling’ force was
not present in the PicoGreen fluorescence quenching
assay and this might explain this discrepancy.
The dissociation properties of the pDNA or siRNA
oligolysine complexes
The stability and dissociation properties of the pDNA/oligoly-
sine and the siRNA/oligolysine complexes were investigated by
an exposure to a range of concentrations of heparin sulphate
(0.02–1.3 U/mL) (Figure 3). Heparin is anionic and competes
with the nucleic acid binding to the cationic linear lysines, lead-
ing to dissociation (28). PicoGreen-labelled pDNA complexes
were prepared with oligolysine peptides at N/P ratios of 0.75:1,
1.5:1, 3:1, 6:1 and 12:1 with pDNA and PicoGreen-labelled
siRNA complexes were prepared at N/P ratios of 1:1, 2:1, 4:1
and 8:1. Complexes were compared for the concentration of
heparin required to restore fluorescence RFU values to 50% of
the naked nucleic acid, representing a 50% dissociation.
Dissociation of the oligolysine pDNA complexes
An increase in the peptide length from K8 to K32
increased the stability of pDNA complexes to dissociation
A B
C D
Figure 1: The binding properties of the linear lysine peptides with plasmid DNA or siRNA. The linear lysine peptides (K8, K16, K24 and
K32) were mixed with 5 kb pDNA (pCI-Luc) or siRNA at different N/P ratios for 30 min. The complexes were then run on the 1% agarose
gel for the pDNA complexes and 4% agarose gel for the siRNA complexes subsequently. (A) The K8 pDNA and K16 pDNA complexes,
(B) the K24 pDNA and K32 pDNA complexes, (C) the K8 siRNA and K16 siRNA complexes and (D) the K24 siRNA and K32 siRNA
complexes. The formulations of the complexes are expressed in an N/P ratio.
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by heparin (Figure 3; Figure S2; Table 1). For K8 pDNA
complexes at an N/P ratio of 3, 0.05 U/mL of heparin was
required to dissociate complexes by 50% (Figure 3A),
while the K16 pDNA complexes required fourfold more
heparin (0.2 U/mL) (Figure 3B) and K24 and K32 pDNA
complexes required 0.35 and 0.4 U/mL of heparin,
respectively (Figure 3C,D). Overall, increasing the size of
the linear lysine peptides enhanced the stability of the pep-
tide/pDNA complexes to dissociation by heparin, indicating
better binding.
At N/P ratios above 3, the dissociation of the oligolysine/
pDNA complexes required higher amounts of heparin,
reflecting their greater stability (Figure 3; Table 1). For
example, only a trace amount of heparin was needed to
dissociate 50% of the K8 pDNA complexes at an N/P
ratio of 1.5, while approximately 0.05, 0.25 and 0.5 U/mL
of heparin were required to achieve 50% dissociation of
the complexes with N/P ratios of 3, 6 and 12, respec-
tively. A similar relationship between complex stability to
heparin and N/P ratios was observed for the K16, K24
and K32 pDNA complexes (Figure 3; Table 1). Interest-
ingly, the K32 pDNA complexes at an N/P ratio of 12
were not dissociated with heparin even at 1.3 U/mL,
implying the tight binding between the peptide and the
pDNA.
The dissociation properties of the siRNA from the
linear lysines
Increasing the oligolysine peptide lengths from K16 to K32
at the same N/P ratios also improved siRNA stability
(Figure 4; Figure S3; Table 2). For example, 0.1 U/mL of
heparin was needed to dissociate 50% of the K16 siRNA
complexes at an N/P ratio of 2 (Figure 4B), while twofold
more heparin (0.2 U/mL) and 5.5-fold more heparin
(0.55 U/mL) were required to dissociate 50% of the K24
siRNA and K32 siRNA complexes, respectively, at the
same N/P ratio (Figure 4C,D). The K8 siRNA complexes,
although less quenched, were more resistant to heparin
dissociation compared to the K16 siRNA complexes,
requiring 0.2 U/mL of heparin at an N/P ratio of 2 for a
50% dissociation (Figure 4A), the same as for K24. The
less quenched K8 may suggest that it has a lower dissoci-
ation constant (Kd) to anionic molecules such as siRNA.
This lower Kd could be due to the fact that K8 has a lower
number of cations per se, which would be consistent to a
previous observation demonstrating that lysine monomers
have a lower binding affinity to pDNA compared to
polylysines (29). When heparin was added, it competed
against the siRNA for the binding to the peptides. In the
case of K16, K24 and K32, they had a stronger affinity to
the heparin under an increased concentration, and hence,
the end result was that the heparin outcompeted the
siRNA in the binding. However, the lower Kd of the K8
peptide means that it did not bind strongly to neither the
siRNA nor heparin. As a result, K8 would constantly bind
and unbind to siRNA/heparin.
Increasing the N/P ratios from 1 to 8 also increased the
resistance of siRNA complexes with all oligolysine peptides
to heparin dissociation. For instance, the K8 siRNA com-
plexes at N/P ratios of 1, 2, 4 and 8 required 0.07, 0.2,
0.35 and 1.02 U/mL heparin to achieve 50% complex dis-
sociation (Figure 4A), while for K16 siRNA complexes at
N/P ratios of 2, 4 and 8, heparin concentrations of 0.1,
0.3 and 0.55 U/mL were needed, respectively (Figure 4B).
For K24 siRNA complexes at N/P ratios of 1, 2, 4 and 8,
A B
Figure 2: The binding of the linear lysine peptides to (A) pDNA and (B) siRNA. The linear lysine peptides were mixed with PicoGreen-
labelled pDNA or siRNA at different N/P ratios for 30 min. The fluorescence intensity of the complexes was then measured and
normalized with the naked pDNA or siRNA. The formulations of the complexes are expressed as an N/P ratio. * denotes a significant
difference between the relative fluorescence unit (RFU) of the K8 pDNA/siRNA complexes and the rest of the complexes (p < 0.05).
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heparin concentrations of 0.05, 0.2, 0.48 and 0.95 U/mL
were required for 50% dissociation, respectively (Fig-
ure 4C). For K32 siRNA complexes with N/P ratios of 1, 2
and 4, 50% dissociation was achieved with heparin con-
centrations of 0.1, 0.55 and 1.02 U/mL, respectively (Fig-
ure 4D). Furthermore, as observed with the K32/pDNA
complexes, no dissociation was observed at the highest
N/P ratio of the K32/siRNA complexes.
Size and zeta potential of the complexes
The average hydrodynamic size of the complexes was
determined by dynamic light scattering at a range of
charge ratios for each oligolysine peptide (K8, K16, K24
and K32) formulated with pDNA (Table 3). Generally, there
was a substantial decrease in size as N/P ratios were
increased from 0.75 to 6. For instance, the average size of
the K16 pDNA complexes decreased from 89 nm to
46 nm. A similar trend was observed for pDNA complexes
formed with K8, K24 and K32 (Table 3).
In terms of the lysine length and the size of the pDNA
complexes, the K8 and K16 pDNA complexes were of
similar sizes for N/P ratios of 1.5, 3 and 6. The K24 pDNA
complexes were larger than the K8 and K16 pDNA com-
plexes (for N/P ratios of 1.5, 3 and 6), while the K32 pDNA
complexes were the largest pDNA complexes for all N/P
ratios. This suggested that longer lysine peptides (i.e.
longer than K16) would form larger pDNA complexes. The
smallest particles were formed by K8 and K16 oligolysine
peptides with pDNA at N/P ratios of 6.
The average zeta potential of the linear lysine peptide
pDNA complexes became increasingly positive with
increases in the N/P ratio from 0.75 to 6 (Table 3). For
instance, increasing the N/P ratio of the K8 pDNA
A B
C D
Figure 3: The dissociation properties of linear lysine pDNA complexes. K8, K16, K24 and K32 were mixed with PicoGreen-labelled
pDNA at different N/P ratios for 30 min. Different concentrations of heparin were added to the complexes, and the fluorescence intensity
of the complexes was measured. (A) The K8 pDNA complexes, (B) the K16 pDNA complexes, (C) the K24 pDNA complexes and (D) the
K32 pDNA complexes. The formulations of the complexes are expressed as an N/P ratio.
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complexes from 0.75 to 6 increased the average zeta
potential of the complexes from 13 mV to +42 mV. A
similar relationship between the N/P ratios and the zeta
potential was observed for the other pDNA complexes
with K16, K24 and K32. It is worth noting that the K8,
K16 and K24 pDNA complexes had positive zeta poten-
tial values although they did not seem to be completely
retarded in the gel retardation assay. This is because the
voltage involved in the zeta potential measurement was
less than the voltage used in the gel retardation assay.
As a result, there was less ‘pulling’ force exerted in the
complexes in the zeta potential measurement, and
hence, the relatively weak complexes could remain
intact.
A general correlation was observed between the length of
the lysine peptides and the zeta potential. Longer oligoly-
sine peptides produced complexes with more positive zeta
potentials. For instance, at N/P ratios of 0.75, 3 and 6, the
K32 pDNA complexes (e.g. +52.6 mV at an N/P ratio of 6)
were the most positive particles, followed by the K24 (e.g.
+47.1 mV at an N/P ratio of 6), K16 (e.g. +41.6 mV at an
N/P ratio of 6) and K8 pDNA complexes (e.g. +32.4 mV at
an N/P ratio of 6), in a descending order. In addition, the
K32 pDNA complexes were cationic at all N/P ratios
tested.
Generally, for each peptide, higher zeta potential values
correlated with smaller particle sizes. However, when
comparing the peptides between them, this was not the
case. For example, the highest zeta potential value of
+53 mV was observed for K32 pDNA complexes at an
N/P ratio of 6, but their size of 65 nm was significantly
greater than that of K16 pDNA complexes at the same
N/P ratio, which had a zeta potential of only +42 mV, but
a size of 46 nm. This suggests that other factors, in addi-
tion to charge, possibly steric interactions, affected the
particle size.
The mean hydrodynamic sizes and zeta potential of com-
plexes formed from the oligolysine peptides and siRNA
could not be determined due to the highly polydisperse
nature of the complexes (polydispersity index = 1). This
suggested that the linear lysine peptides formed highly
irregular complexes or a wide range of different-sized
complexes with siRNA.
The physical structure of the complexes
To further characterize the physical structures of the com-
plexes, transmission electron microscopy (TEM) was per-
formed. All the linear lysine peptides used in the study
formed complexes with pDNA with a size ranging from 50
to 100 nm (Figure 5A–D). While the K8 pDNA complexes
were mainly spherical or rope-like shaped (length close to
100 nm or longer), we observed toroidal and shorter rod-
shaped (length close to 50 nm) pDNA complexes from
K16, K24 and K32 complexes.T
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When investigating the physical structures of the siRNA
complexes (Figure 6A–E), we found that all the lysine
peptides formed large aggregates with siRNA, instead
of forming monodisperse nanoparticles. This observation
is consistent with the hydrodynamic size measure-
ments.
Cell binding and internalization of oligolysine
formulations
Oligolysine pDNA formulations were prepared with pDNA
labelled with Cy5 at an N/P ratio of 3 and incubated with
Neuro-2A cells for 4 h and then analysed by flow cytome-
try (Figure 7A–D). Cells were also stained with PI to distin-
guish live cells from dead cells. It was found that cell
binding of K8 complexes was very poor, with only 5% of
live cells associated with Cy5-labelled complexes. How-
ever, complexes containing K16, K24 and K32 peptides
were associated with 35%, 61% and 55% of live cells,
respectively (Figure 7A–D). Complexes with K32 appeared
to be associated with an increased number of dead cells
(19%) compared to K8, K16 and K24 formulations with
14%, 11% and 12%, respectively, suggesting that some
cytotoxicity was associated with the longest oligolysine
peptide.
Cells were transfected with Cy5-labelled complexes con-
taining the oligolysine peptides (an N/P ratio of 3:1) and
analysed by confocal microscopy. Analysis revealed that
Cy5-labelled particles within the cells treated with K16 for-
mulations localized into the cytoplasm and perinuclear
regions (Figure 8). Similar patterns were observed with
K24 and K32 peptides, but for K8 formulations, no Cy5-
labelled cells were detected. This evidence was consistent
with flow cytometry data which showed that K16, K24 and
K32 pDNA complexes were capable of entering cells
within 4 h of incubation, while K8 peptide pDNA com-
plexes mostly failed to enter cells.
A B
C D
Figure 4: The dissociation properties of linear lysine siRNA complexes. K8, K16, K24 and K32 were mixed with PicoGreen-labelled
siRNA at different N/P ratios for 30 min. Different concentrations of heparin were added to the complexes, and the fluorescence intensity
of the complexes was measured. (A) The K8 siRNA complexes, (B) the K16 siRNA complexes, (C) the K24 siRNA complexes and (D) the
K32 siRNA complexes. The formulations of the complexes are expressed as an N/P ratio.
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To compare the siRNA delivery efficiency of the oligolysi-
nes, the lysine peptides were prepared with siRNA labelled
with Cy3 and incubated with Neuro-2A cells for 4 h and
then analysed by flow cytometry. However, we did not
observe any oligolysine siRNA complex uptake by the cells
(data not shown).
Transfection studies of the lysine-based peptide
pDNA complexes
The K16 pDNA complexes mediated detectable transfec-
tion levels at an N/P ratio of 3, with a small increase
(1.3-fold) in transfection efficiency at an N/P ratio of 6
(Figure 9). However, the transfection efficiency decreased
when the N/P ratios were further increased to 12 and 24.
The K24 pDNA complexes transfected cells starting from
an N/P ratio of 1.5 with similarly effective transfection at
N/P ratios of 3 and 6. Further increases in the N/P ratio
of K24 pDNA complexes decreased their transfection effi-
ciency. The K32 pDNA complexes achieved optimal
transfection efficiency at an N/P ratio of 3, and again,
increasing the N/P ratio of these complexes decreased
the transfection efficiency. K8 pDNA complexes only
achieved a detectable transgene expression at an N/P
ratio of 12:1. In summary, K16 at an N/P ratio of 3 was
effective for pDNA delivery; however, increasing the
length to K24 and K32 did not further improve the trans-
fection efficiency.
Cytotoxicity mediated by the transfection using the linear
lysine peptides at different N/P ratios was further analysed
(Figure 10). There was a trend that the pDNA complexes
formed by K8, K16 and K24 would mediate <10% of cell
death, while the K32 pDNA complexes were significantly
more toxic than other complexes, inducing up to 50% of
cell toxicity (N/P ratios of 3:1 and 6:1) 24 h post-transfec-
tion.
Gene silencing of the lysine-based peptide siRNA
complexes
The results of the siRNA transfection using the oligolysine
peptides revealed no significant luciferase knockdown,
whereas commercial Lipofectamine 2000 (L2000) siRNA
complexes induced 80% gene knockdown (Figure S4).
Discussion
Oligolysine peptides have been under investigation as
components of vector formulations for the packaging and
delivery of both pDNA and siRNA (10–19,22,24,30–33).
Despite reports showing that these peptides can deliver
both kinds of nucleic acid to cells, systematic studies on
the relationship between the nucleic acid and peptide
structure with complex formation, stability and transfection
efficiency have been limited. Such interactions and optimal
requirements might be expected to differ considerablyT
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owing to the considerable size differences between the
two nucleic acids and to their different subcellular sites of
activity (1). In this study, linear oligolysine peptides with
four different lengths (K8, K16, K24 and K32) were sys-
tematically compared for their interactions with both siRNA
and pDNA. This should allow us to understand the impli-
cations of the differences in the physical structures, chemi-
cal components and sites of activity in delivering the
nucleic acids. Understanding such implications is crucial
for further developing optimal peptide-based nucleic acid
delivery systems that could easily be modified to acquire
specific functionalities such as cell specific targeting and
biocompatibility (2,12,13,30).
An effective pDNA transfection reagent would demonstrate
certain biophysical properties when forming complexes
with pDNA. Such properties include the ability to package
pDNA, unload pDNA and form small, discrete, stable parti-
cles. Studies were performed to investigate the ability of
each peptide to package the nucleic acids at a range of
charge ratios, calculated from the N/P ratios for each for-
mulation. We observed that each peptide formed pDNA
complexes at an N/P ratio of 3, despite the fact that
longer peptides bound to pDNA with a greater affinity (e.g.
in the PicoGreen fluorescence assay, K24 and K32
achieved similarly high levels of quenching (~90%) than
K16 (~85%) or K8 (~75%)). Such findings were consistent
with others (15,16,34–36), although different lysine lengths
were used in other studies. Taken together, we identified a
trend that the longer the lysine lengths, the more compact
the pDNA complexes.
A necessary corollary of efficient pDNA packaging is that
for efficient gene expression, the oligolysine peptide must
release the pDNA within the cell into the nucleus. To com-
pare particle stability and dissociation potential, oligolysine
complexes with pDNA were incubated with anionic hep-
arin, mimicking the intracellular environment where high
concentrations of anions may be encountered, such as
RNA, DNA, sialic acid (16,30). Complexes were preformed
Table 3: The average hydrodynamic size and zeta potential of the linear lysine pDNA complexes
N/P ratios
Average diameter (nm) Zeta potential (mV)
K8 K16 K24 K32 K8 K16 K24 K32
0.75 98  3.8 89.3  1.6 79.5  1.6 156.9  4.1 17.4  1 13.3  1 10.4  1 23  0.6
1.5 66  1.1 64.8  1.2 68.4  1.2 87.4  6.3 27.1  0.9 33.5  1 29.1  0.9 34.5  1 .2
3 55.4  1.0 55.4  0.4 63.6  1 72.4  4.3 34.3  0.7 38.6  2.3 38.9  0.6 11.6  2.5
6 47.9  0.7 46.5  0.9 53.7  0.9 65.4  1.8 32.4  2.7 41.6  1.6 47.1  2.2 52.6  4
A B
C D
Figure 5: The physical structure of the
pDNA complexes. The complexes were
prepared at an N/P ratio of 3:1 and were
applied onto a glow-discharged 300-mesh
copper grid coated with a Formvar/carbon
support film. The complexes were stained
with 1% uranyl acetate before blotting with
filter paper and air-dried. (A) The K8 pDNA
complexes, (B) the K16 pDNA complexes,
(C) the K24 pDNA complexes and (D) the
K32 pDNA complexes. The bar represents
100 nm.
756 Chem Biol Drug Des 2016; 87: 747–763
Kwok et al.
with PicoGreen-labelled pDNA to achieve maximal
quenching and then incubated with increasing concentra-
tions of heparin, and stability was quantified as the amount
of heparin required to restore fluorescence levels to 50%
of naked pDNA. The heparin dissociation assay indicated
complex stability at the same N/P ratio in the order of
A B
D E
C
Figure 6: The physical structure of the pDNA complexes. The complexes were prepared at an N/P ratio of 4:1 and were applied onto a
glow-discharged 300-mesh copper grid coated with a Formvar/carbon support film. The complexes were stained with 1% uranyl acetate
before blotting with filter paper and air-dried. (A) siRNA alone, (B) the K8 siRNA complexes, (C) the K16 siRNA complexes, (D) the K24
siRNA complexes and (E) the K32 siRNA complexes. The bar represents 100 nm.
A B
C D
Figure 7: Cellular binding/uptake
efficiencies of linear lysine pDNA complexes.
Neuro-2A cells were seeded 24 h before
transfection. The complexes were made by
mixing the peptides with Cy5-labelled pCI-
Luc for 30 min. Following the removal of full
growth medium, complexes were overlaid to
the cells for 4 h. The cells were harvested
for analysis after transfection. For flow
cytometry analysis, propidium iodide (PI) was
used to estimate the cell viability following
transfection: (A) cells exposed to K8 pDNA
complexes at 3:1 N/P ratio, (B) cells
exposed to K16 pDNA complexes at 3:1 N/
P ratio, (C) cells exposed to K24 pDNA
complexes at 3:1 N/P ratio and (D) cells
exposed to K32 pDNA complexes at 3:1 N/
P ratio.
Chem Biol Drug Des 2016; 87: 747–763 757
Systematic Comparisons of Formulations
K32 > K24 > K16 > K8. For example, at the optimal N/P
ratio of 3 for packaging, the concentrations increased from
0.1 U/mL for K8, to 0.2 U/mL for K16 and 0.4 U/mL for
both K24 and K32 peptides. Therefore, higher concentra-
tions of heparin were required to dissociate complexes for-
mulated with longer lysines at the same N/P ratios,
suggesting that those complexes would be more stable to
dissociation in both the extracellular and intracellular envi-
ronments.
Biophysical analysis of pDNA complexes revealed that at
sufficiently high N/P ratios, all oligolysine reagents used in
this study formed stable, positively charged pDNA com-
plexes. Similar to the observation from others (15,37,38),
we found that longer lysine peptides tended to form larger
pDNA complexes with sizes ranging from <50 nm for K8
peptides to 72 nm for K32 peptides at an N/P ratio of 3,
and a similar pattern at other charge ratios. Larger pep-
tides also formed complexes with higher zeta potential val-
ues than those made with shorter peptides ranging from
+34 mV for K8 complexes to +42 mV for K32 complexes
at the N/P ratio of 3. Thus, longer peptides were forming
larger particles with higher zeta potential values. The data
from TEM confirmed that all the lysine peptides formed
uniform nanoparticles with pDNA. The K8 pDNA
complexes were mainly in the less compact spherical and
rope-like (length close to 100 nm or longer) shapes, while
the K16, K24 and K32 complexes were in the more com-
pact shorter rod (length close to 50 nm) and toroidal
forms. The longer lysine peptides are more effective in
condensing pDNA because they can provide more cations
for pDNA binding (39,40).
Interactions of oligolysine peptide/pDNA complexes with
cells were then investigated, from cell binding and uptake
to transfection efficiencies. The biophysical analysis had
suggested that at an N/P ratio of 3, all the complexes
were positively charged, which would permit charge-
mediated cell binding, and small enough to be internalized
by clathrin- or caveolae-mediated endocytosis, the first
steps in the transfection pathway (41–43). Analysis of cell
binding and uptake by flow cytometry for oligolysine com-
plexes containing Cy5-labelled pDNA revealed that pDNA
complexes made with K16, K24 and K32 peptides were
efficiently taken up by cells, with K32 complexes displaying
more toxicity, while K8 complexes were poorly taken up.
A B C
D E
Figure 8: Cellular uptake and localization of linear lysine pDNA complexes. Neuro-2A cells were transfected at an N/P ratio of 3:1 as
described in Figure 7. For confocal microscopy, cells were washed and stained with phalloidin for the F-actin on the cell membrane
(green), DAPI for the nucleus (blue) and Cy5 for the complexes (red). (A) Untreated cells, (B) cells exposed to K8 pDNA complexes, (C)
cells exposed to K16 pDNA complexes, (D) cells exposed to K24 pDNA complexes and (E) cells exposed to K32 pDNA complexes. Scale
bar = 15 lm.
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The toxicity of the K32 peptide can be explained by the
fact that K32 has a strong affinity to pDNA, which may in
turn result in excessive binding of genomic pDNA in cells,
upsetting the gene regulation and eventually causing cell
death. Confocal fluorescence microscopy analysis of K16,
K24 and K32 pDNA complexes further revealed that
Cy5-labelled pDNA was detectable within cells after 4 h
of incubation at 37 °C, while no plasmid uptake was
detectable with K8 pDNA complexes. Cell uptake studies
suggested that the low stability of K8 pDNA complexes
may have dissociated at the cell surface due to electro-
static forces of anionic surface moieties such as glycopro-
teins, sialic acid as reported for other poor efficiency
formulations (44). Being rope-like and spherical in shapes,
the K8 pDNA complexes are less favourable for endocyto-
sis compared to the more compact toroid and shorter rod
pDNA particles (45,46). Luciferase reporter gene transfec-
tion was detected from incubations of pDNA complexes
with peptides K16, K24 and K32, at optimal N/P ratios of
3 or 6. K8 complexes, however, displayed very low trans-
fection levels across the full range of charge ratios (0.75–
24), consistent with the poor efficiency of binding and
uptake (47–49).
Peptides K8, K16, K24 and K32 all formed small, cationic,
stable nanoparticles, but differed in the efficiency of pDNA
packaging in proportion to the oligolysine length. The ease
of dissociation of the same complexes was inversely propor-
tional to peptide length (34–36). Overall, in cell transfection
studies, peptide K16 appeared to offer the minimum effec-
tive oligolysine peptide length in pDNA complexes, with the
ideal balance of particle size, stability and charge permitting
cell binding, uptake and transfection. However, the biophys-
ical differences between K16, K24 and K32 were quite
subtle, which was reflected in their similar transfection effi-
ciencies, while the K8 peptide pDNA complexes appeared
not to package as well as the other peptides, or provide sta-
bility to heparin challenge, which were the major biophysical
correlations with the poor transfection efficiency.
Studies on the biophysical characteristics and delivery of
the oligolysine siRNA complexes revealed a different story to
the pDNA complexes. PicoGreen fluorescence quenching
Figure 9: Plasmid transfection efficiency mediated by linear lysine pDNA complexes. Neuro-2A cells were seeded 24 h before
transfection. The complexes were made by mixing peptides (K8, K16, K24 and K32) with pCI-Luc in different N/P ratios for 30 min.
Following removal of the full growth medium, complexes were overlaid to the cells for 4 h. After removing the transfection complexes, the
full growth medium was added to the cells. Luciferase expression in the cells was analysed 24 h post-transfection to estimate the
transfection efficiencies of the complexes. The formulations of the complexes are expressed as an N/P ratio. * denotes the significant
difference in the RLU/mg between the untreated cells and the transfected cells (p < 0.05).
Figure 10: Cytotoxicity induced by transfection of linear lysine
pDNA complexes. Neuro-2A cells were seeded 24 h before
transfection. The complexes were made by mixing peptides (K8,
K16, K24 and K32) with pCI-Luc in different N/P ratios for
30 min. Following removal of the full growth medium, complexes
were overlaid to the cells for 4 h. After removing the transfection
complexes, the full growth medium was added to the cells. Cell
viability was analysed 24 h post-transfection to estimate the
cytotoxicity caused by the transfection. The formulations of the
complexes are expressed as an N/P ratio. * and *** denote the
significant difference in the cell viability between the untreated
cells and the transfected cells at p < 0.05 and p < 0.001,
respectively.
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assays showed that the lysine peptides appeared to associ-
ate with the siRNA with maximal fluorescence quenching at
N/P ratios around 2–4, as observed with pDNA. However,
the extent of packaging with K8 was significantly lower than
that for the other three peptides. Gel retardation assays
revealed a smear of siRNA complexes formed with K8 and
K16 at all N/P ratios tested, whereas peptides K24 and K32
may completely retard the siRNA to the wells at very high N/
P ratios between 24 and 32. When the N/P ratio of K24 and
K32 was further increased, the complexes migrated to the
cathode. These data were consistent to the failed attempts
at measuring particle size and charge due to high polydis-
persity of all complexes. The nature of the high polydisper-
sity of all the complexes was confirmed by the TEM. While
the oligolysines could bind to siRNA, the peptides might not
be able to form a particle with a positive surface charge. As
a result, all the particles formed at the initial stage of com-
plex formation would aggregate under van der Waal’s forces
(15). Therefore, linear lysine peptides were not able to pack-
age the siRNA to form complexes with the optimal size and
shape for cellular uptake (45,46). Unsurprisingly, delivery of
luciferase siRNA to Neuro-2A-Luc cells failed to induce luci-
ferase silencing. This study shows that linear lysine pep-
tides, without any other components, are efficient and
potentially useful reagents for packaging and delivery of
pDNA, but not siRNA. This difference may be explained by
the relatively small size and greater rigidity of siRNA com-
pared to those of pDNA. siRNA is a double-stranded nucleic
acid with 21–23 base pairs. Compared to the much larger
pDNA (usually 1–10 kb), siRNA has limited opportunity for
intermolecular electrostatic interactions with cationic oligoly-
sine peptides. Furthermore, the length of siRNA is approxi-
mately 6 nm, which is considerably shorter than its 70 nm
persistence length (persistence length is the minimum
length required for a double-stranded nucleic acid to fold in
any given direction). Therefore, siRNA is a rigid and inflexible
structure with minimum rotational freedom (50,51). How-
ever, pDNA (its persistence length = 40–50 nm) is consider-
ably longer than its persistence length and therefore has a
structure that allows it to fold more flexibly (52). To package
siRNA, a structure with high folding flexibility may be
required to encapsulate the small nucleic acid. The linear
lysine peptides used in this study are short and of limited
folding flexibility; this may explain why they are incapable of
condensing siRNA into monodisperse complexes for func-
tionality.
Overall, our results have shown that the generic belief that
higher molecular weight cationic polymers would confer a
better binding and condensing of nucleic acids for better
delivery is incomplete and that we need to consider the
physical structure as well as the number of charges on the
nucleic acid delivery agent according to the type of nucleic
acids to be delivered. In the case of siRNA delivery, a
branched structure may be more favourable than a linear
structure because a branched structure has higher rotational
freedom (2,19,53). Indeed, we have observed that a
small-branched lysine peptide is able to package siRNA into
monodisperse complexes (data not shown). Previously, we
demonstrated that branched PEI is more effective in siRNA
packaging and delivery compared to linear PEI (1). Other
studies have also shown that larger and branched polymers
such as hyperbranched polylysines (54), dendrimers (55),
branched PEI (1,56), histidylated polylysine peptides (57–61)
and chitosan (27,62), which all are large-branched struc-
tures, are all useful for siRNA delivery. This may indicate that
a flexible structure would be more able to package and deli-
ver siRNA. Further studies to elucidate the structure–function
relationship of the degree of branched reagents and siRNA
or DNA delivery would help improve the current nucleic acid
delivery systems.
Conclusions
The effects of different lysine peptide lengths on pDNA and
siRNA packaging and delivery were studied. Four linear
oligolysines, K8, K16, K24 and K32, were used. We demon-
strated by fluorescence quenching and gel shift assays,
dynamic light scattering, laser Doppler anemometry and
TEM that the oligolysine peptides formed positively charged
monodisperse complexes with pDNA although K8 formula-
tions were less quenched and less resistant to heparin dis-
sociation assays and consequently displayed poor
transfection efficiency. In these experiments, the K16 pep-
tides were the minimally effective peptides for stable particle
formation and optimal transfection efficiency. For siRNA
packaging, evidence from gel shift assays, dynamic light
scattering and TEM indicated that all the linear oligolysines
tested were not able to package siRNA to form monodis-
perse complexes, and consequently, siRNA transfection
was unsuccessful. The inability of the oligolysines to con-
dense siRNA could be due to the relatively small size and
greater rigidity of the siRNA, and therefore, a more flexible
structure such as branched polymers or dendrimers could
be more useful to condense siRNA. All in all, our results indi-
cate that the length and the physical structure of the pep-
tides and the charge ratio are integral parameters to
consider for effective packaging and delivery of nucleic
acids such as plasmid DNA and siRNA.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. The binding of the linear lysine peptides to (A)
pDNA and (B) siRNA at lower N/P ratios.
Figure S2. The dissociation properties of linear lysine
pDNA complexes.
Figure S3. The dissociation properties of linear lysine
siRNA complexes.
Figure S4. siRNA transfection efficiency mediated by the
linear lysine peptides with siRNA complexes.
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